S16-443 Prodrugs of PKC modulators for improved formulation, therapeutic efficacy and tolerability Researchers at Stanford have developed prodrug derivatives of protein kinase C (PKC) modulators that have lower toxicity and are more effective than the parent compound. PKC modulators are being developed to treat a variety of diseases. Paul Wender Nancy Benner Katherine Keenan Jack Sloane Xiaoyu Zang
S15-370 Cell-Penetrating, Guanidinium-Rich Oligomers for Drug and Probe Delivery Stanford researchers have synthesized a highly effective molecule to transport drug conjugates across cell membranes. Colin McKinlay Paul Wender Robert Waymouth